TP53 Tumor Protein P53
Guardian of the Genome: Key Tumor Suppressor Gene in Cancer Biology
Gene Information Card
| Symbol | TP53 |
|---|---|
| Full Name | Tumor Protein P53 |
| Gene Type | Protein coding |
| Chromosomal Location | 17p13.1 |
| NCBI Gene ID | 7157 ncbi.nlm.nih.gov/gene/7157 |
| Ensembl ID | ENSG00000141510 |
| UniProt ID | P04637 |
| OMIM ID | 191170 |
| HGNC ID | 11998 |
| Aliases | P53, BCC7, LFS1, TRP53 |
Description
TP53 encodes the tumor suppressor protein p53, a transcription factor that regulates cell cycle arrest, apoptosis, senescence, DNA repair, and metabolism in response to cellular stress. It is frequently mutated in human cancers, with over 50% of all tumors harboring TP53 alterations. Loss of p53 function contributes to genomic instability and tumor progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Li-Fraumeni syndrome | Germline TP53 mutations lead to loss of tumor suppression, predisposing to multiple early-onset cancers | OMIM #151623 |
| Breast cancer | Somatic TP53 mutations impair DNA damage response and apoptosis, promoting tumorigenesis | COSMIC; ClinVar |
| Colorectal cancer | TP53 loss of function allows evasion of apoptosis and continued proliferation despite DNA damage | NCBI Gene; COSMIC |
| Lung cancer | TP53 mutations are common in non-small cell lung cancer, associated with poor prognosis | ClinVar; COSMIC |
| Ovarian cancer | High-grade serous ovarian carcinoma frequently shows TP53 mutations, driving genomic instability | COSMIC; OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Spleen | 10.2 | Medium |
| Lymph node | 9.8 | Medium |
| Bone marrow | 8.5 | Medium |
| Brain | 4.3 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (lung carcinoma) | 15.0 | High expression |
| MCF7 (breast carcinoma) | 12.3 | Medium expression |
| HeLa (cervical carcinoma) | 10.1 | Medium expression |
| HCT116 (colorectal carcinoma) | 14.5 | High expression |
| K562 (leukemia) | 9.0 | Medium expression |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| p.R175H | Missense | ~5% in COSMIC | Loss of DNA binding; gain of oncogenic functions |
| p.R248W | Missense | ~4% in COSMIC | Loss of transactivation; dominant negative effect |
| p.R273H | Missense | ~6% in COSMIC | Loss of DNA binding; gain of function |
| p.G245S | Missense | ~3% in COSMIC | Structural disruption; loss of function |
| p.R337H | Missense | ~1% in COSMIC | Altered oligomerization; associated with Li-Fraumeni-like syndrome |
Mutation functional classification
Loss of Function (LOF)
Most common; missense mutations in DNA-binding domain (e.g., R175H, G245S) abolish transcriptional activity, impairing cell cycle arrest and apoptosis.
Gain of Function (GOF)
Certain mutants (e.g., R175H, R273H) acquire new oncogenic properties, promoting invasion, metastasis, and chemoresistance independent of wild-type p53.
Dominant Negative (DN)
Mutant p53 can oligomerize with wild-type p53, inhibiting its function in heterozygous cells, often seen in Li-Fraumeni syndrome.
View complete mutation data:
Gene Ontology (GO)
| • DNA-binding transcription factor activity (GO:0003700) | • Protein binding (GO:0005515) |
| • Apoptotic process (GO:0006915) | • Cell cycle arrest (GO:0007050) |
| • DNA damage response (GO:0006974) |
Pathways
• p53 signaling pathway (KEGG hsa04115)
• Apoptosis (KEGG hsa04210)
• Cell cycle (KEGG hsa04110)
• miRNAs in cancer (KEGG hsa05206)
Protein Summary
The p53 protein (UniProt P04637) is a 393-amino acid transcription factor with N-terminal transactivation domain, central DNA-binding domain, tetramerization domain, and C-terminal regulatory domain. It acts as a homotetramer to regulate hundreds of target genes involved in cell cycle control, apoptosis, DNA repair, and metabolism. Post-translational modifications (phosphorylation, acetylation) modulate its stability and activity. Mutations predominantly cluster in the DNA-binding domain, disrupting sequence-specific DNA binding.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| TP53BP2 Knockout HEK293 Cell Line | EDJ-KQ1381 | Human | 7159 | Details Get a Quote |
| TP53BP1 Knockout HEK293 Cell Line | EDJ-KQ3793 | Human | 7158 | Details Get a Quote |
| TP53I11 Knockout HEK293 Cell Line | EDJ-KQ6629 | Human | 9537 | Details Get a Quote |
| TP53I3 Knockout HEK293 Cell Line | EDJ-KQ6637 | Human | 9540 | Details Get a Quote |
| TP53I13 Knockout HEK293 Cell Line | EDJ-KQ10577 | Human | 90313 | Details Get a Quote |
| TP53INP1 Knockout HEK293 Cell Line | EDJ-KQ11304 | Human | 94241 | Details Get a Quote |
| TP53TG3B Knockout HEK293 Cell Line | EDJ-KQ15097 | Human | 729355 | Details Get a Quote |
| TP53AIP1 Knockout HEK293 Cell Line | EDJ-KQ15888 | Human | 63970 | Details Get a Quote |
| TP53INP2 Knockout HEK293 Cell Line | EDJ-KQ15889 | Human | 58476 | Details Get a Quote |
| TP53TG3C Knockout HEK293 Cell Line | EDJ-KQ15890 | Human | 653550 | Details Get a Quote |
| TP53TG3D Knockout HEK293 Cell Line | EDJ-KQ15891 | Human | 729264 | Details Get a Quote |
| TP53TG3E Knockout HEK293 Cell Line | EDJ-KQ15892 | Human | 102724101 | Details Get a Quote |
| TP53TG3F Knockout HEK293 Cell Line | EDJ-KQ15893 | Human | 102724127 | Details Get a Quote |
| TP53 Knockout HEK293 Cell Line | EDJ-KQ17910 | Human | 7157 | Details Get a Quote |
Displaying Records 1 To 15 Of 93 Records
- 1
- 2
- Next Page »